Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Adoptive cell transfer (ACT) of genetically engineered T cells expressing cancer-specific T-cell receptors (TCR) is a promising cancer treatment. Here, we investigate the in vivo functional activity and dynamics of the transferred cells by analyzing samples from 3 representative patients with melanoma enrolled in a clinical trial of ACT with TCR transgenic T cells targeted against the melanosomal antigen MART-1. The analyses included evaluating 19 secreted proteins from individual cells from phenotypically defined T-cell subpopulations, as well as the enumeration of T cells with TCR antigen specificity for 36 melanoma antigens. These analyses revealed the coordinated functional dynamics of the adoptively transferred, as well as endogenous, T cells, and the importance of highly functional T cells in dominating the antitumor immune response. This study highlights the need to develop approaches to maintaining antitumor T-cell functionality with the aim of increasing the long-term efficacy of TCR-engineered ACT immunotherapy. Significance: A longitudinal functional study of adoptively transferred TCR–engineered lymphocytes yielded revealing snapshots for understanding the changes of antitumor responses over time in ACT immunotherapy of patients with advanced melanoma. Cancer Discov; 3(4); 418–29. ©2013 AACR. See related commentary by Speiser, p. 379 This article is highlighted in the In This Issue feature, p. 363
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Phenotype and function of human T lymphocyte subsets: Consensus and issues
Appay, V., van Lier, R. A. W., Sallusto, F., & Roederer, M. (2008) · Cytometry Part A · doi:10.1002/cyto.a.20643 · Cited by 729 · cited 1×
“Naïve cells were classified as CD45+/CCR7+/CCR5−/PD1−, CD27+/ CD28−/CD62L+, and CD45+/CCR7+/CCR5−/PD1+; central memory as CD45RO−/ CD25−/HLA-DR−/CD127+; effector memory as CD45−/ CCR7−/CCR5+/PD1+, CD45−/ CCR7−/CCR5−/PD1+, CD45−/CCR7−/ CCR5−/PD1−, CD45−/CCR7−/CCR5−/PD1−, and CD27−/CD28−/ CD62L−; effector memory RA (EMR…”
Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591 · cited 1×
“Melanoma frequently expresses proteins of the pigmented pathway, reminiscent of its normal counterpart, the melanocytes, representing lineage-specific antigens such as tyrosinase, MART-1/Melan-A, or gp100, which have been validated as targets for T-cell responses to melanoma (1).”
BackgroundSelf-citationMa, C., Fan, R., Ahmad, H., Shi, Q., Comin-Anduix, B., Chodon, T., Koya, R. C., Liu, C.-C., Kwong, G. A., Radu, C. G., et al. (2011) · Nature Medicine · doi:10.1038/nm.2375 · Cited by 441 · cited 21×
“The FACS/SCBC analysis permits such separation, but the FACS step requires a longer time before SCBC loading, which could lead to the loss of protein signal.”
BackgroundMethodInfluentialSelf-citationCD8+ T cell efficacy in vaccination and disease
Appay, V., Douek, D. C., & Price, D. A. (2008) · Nature Medicine · doi:10.1038/nm.f.1774 · Cited by 393
Huang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0407 · Cited by 157 · cited 1×
“Immunohistochemical staining was conducted following standard methods as previously described (34, 35).”
MethodSelf-citation
Cited by
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Self-citationThommen, D. S., & Schumacher, T. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.012 · Cited by 1,299
Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19
Su, Y., Chen, D., Yuan, D., Lausted, C., Choi, J., Dai, C. L., Voillet, V., Duvvuri, V. R., Scherler, K., Troisch, P., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.037 · Cited by 589
Self-citationSingle-cell analysis tools for drug discovery and development
Heath, J. R., Ribas, A., & Mischel, P. S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.16 · Cited by 473
“These assays are being applied to the characterization of T cell responses to cancer induced by several immunotherapy approaches 99,103 .”
InfluentialSelf-citationT Cell Dysfunction in Cancer Immunity and Immunotherapy
Xia, A., Zhang, Y., Xu, J., Yin, T., & Lu, X.-J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 341
Metadata
- Authors
- Ma, C., Cheung, A. F., Chodon, T., Koya, R. C., Wu, Z., Ng, C., Avramis, E., Cochran, A. J., Witte, O. N., Baltimore, D., Chmielowski, B., Economou, J. S., Comin-Anduix, B., Ribas, A., & Heath, J. R.
- Venue
- Cancer Discovery
- Published
- 2013-04-01
- Volume
- 3
- Issue
- 4
- Pages
- 418-429
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2100634642
- Cited by
- 144
- References
- 9
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy. https://app.cochat.ai/papers/10.1158/2159-8290.cd-12-0383
- The paper
- Ma, C., Cheung, A. F., Chodon, T., Koya, R. C., Wu, Z., Ng, C., Avramis, E., Cochran, A. J., Witte, O. N., Baltimore, D., Chmielowski, B., Economou, J. S., Comin-Anduix, B., Ribas, A., & Heath, J. R. (2013). Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-12-0383
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.